Denali Therapeutics Inc. 4

Denali Therapeutics CEO Ryan J. Watts made a charitable gift of 32,220 shares of DNLI common stock from an indirect trust holding.

On August 12, 2026, Denali Therapeutics Inc. President and CEO Ryan J. Watts reported an in-kind charitable gift of 32,220 shares of Denali Therapeutics common stock, transferred from indirect ownership via the Watts Family 2015 Trust to a donor advised fund. The transaction, coded as a disposition for gift (code G), did not involve any sale proceeds and thus has no per-share price or cash value disclosed on the Form 4. Following the contribution, Watts reported indirect beneficial ownership of 2,120,384 shares held by the trust and direct ownership of 296,833 shares, which include 184,915 unvested RSUs, indicating he continues to retain a substantial equity stake in the company.

Filing Facts

CIK

1714899

Ticker

DNLI

Form

4

Source Type

fda

Accession

0001724310-26-000007

Alert Tier

4